Scientific Reports · 2019 · 26 citations · 34 references
MedicineGeneticsOncologyCancer GeneticsMolecular OncologyOncogenesCancer GenomicsGenetic DisordersOncogene MutationsOncogenic Signaling PathwaysRas Family OncogenesSmall Gtpase SignalingBiophysical CharacterizationInsertionsOncogenic Ras MutationsOncogenic Ras SignalingRas SignalingRas Signaling ActivationRas Signaling PathwaySomatic Mutations
Mutations in the RAS genes are identified in a variety of clinical settings, ranging from somatic mutations in oncology to germline mutations in developmental disorders, also known as 'RASopathies', and vascular malformations/overgrowth syndromes. Generally single amino acid substitutions are identified, that result in an increase of the GTP bound fraction of the RAS proteins causing constitutive signalling. Here, a series of 7 in-frame insertions and duplications in HRAS (n = 5) and KRAS (n = 2) is presented, resulting in the insertion of 7-10 amino acids residues in the switch II region. These variants were identified in routine diagnostic screening of 299 samples for somatic mutations in vascular malformations/overgrowth syndromes (n = 6) and in germline analyses for RASopathies (n = 1). Biophysical characterization shows the inability of Guanine Nucleotide Exchange Factors to induce GTP loading and reduced intrinsic and GAP-stimulated GTP hydrolysis. As a consequence of these opposing effects, increased RAS signalling is detected in a cellular model system. Therefore these in-frame insertions represent a new class of weakly activating clinically relevant RAS variants.
34
Ahmet Zehir, Ryma Benayed, Ronak Shah et al. · Nature Medicine · 2017 · 3.5K citations
A Comprehensive Survey of Ras Mutations in Cancer
Ian A. Prior, Paul D. Lewis, Carla Mattos · Cancer Research · 2012 · 2.1K citations · Full text